Watch Dr Ilan Melnick discuss the use of long-acting injectables for schizophrenia including patient suitability, how often they should be followed up in practice, even if they are receiving Abilify Asimtufii every two months,1 and when Abilify Asimtufii may not be suitable.
Abilify Asimtufii PBS Information: Authority required (STREAMLINED) Code: 16456 for Schizophrenia. This product is not listed on the PBS for the treatment of Bipolar I disorder
Please review Approved Product Information before prescribing. Product Information is available here or by calling Lundbeck on 1300 721 277
Abilify Asimtufii® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Level 2/9 Help St, Chatswood NSW 2067, Abilify Asimtufii® is co-commercialised by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Ltd.
.
